CIK 0001593899
- Non-accelerated filer
- Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 460574869
- Phone
- +1 857-284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion | +42,083 | 94,164 | ||
| 2026-01-31 | Vavricka John Chief Commercial Officer | Shares withheld for taxes | −11,570 | $4.24 | $49K | 82,594 |
| 2026-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion · Restricted Stock Units | −33,333 | 0 | ||
| 2026-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion · Restricted Stock Units | −8,750 | 0 | ||
| 2026-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +119,520 | 119,520 | ||
| 2025-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion | +33,333 | 54,848 | ||
| 2025-01-31 | Vavricka John Chief Commercial Officer | Grant or award | +8,750 | 63,598 | ||
| 2025-01-31 | Vavricka John Chief Commercial Officer | Shares withheld for taxes | −11,517 | $3.06 | $35K | 52,081 |
| 2025-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion · Restricted Stock Units | −33,333 | 33,333 | ||
| 2025-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Restricted Stock Units | +8,750 | 8,750 | ||
| 2025-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +132,800 | 132,800 | ||
| 2024-02-01 | Vavricka John Chief Commercial Officer | Sale | −11,819 | $3.84 | $45K | 21,515 |
| 2024-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion | +33,334 | 33,334 | ||
| 2024-01-31 | Vavricka John Chief Commercial Officer | Exercise or conversion · Restricted Stock Units | −33,334 | 66,666 | ||
| 2024-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +132,800 | 132,800 | ||
| 2023-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2023-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2022-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2021-01-29 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +117,300 | 117,300 | ||
| 2020-11-03 | Vavricka John Chief Commercial Officer | Conversion | +82,508 | 82,508 |
Page 1 of 2 · 21 trades